Clinical Trials Logo
  1. Home
  2. Behçet Disease
  3. NCT04528082

Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease — BEAN  

Behçet Disease Clinical Trial

Official title:
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet's Disease (BEAN)

Clinical Trial Summary

The aim of this study is to estimate the efficacy of apremilast compared to placebo in the treatment of oral ulcers in pediatric participants from 2 to < 18 years of age with oral ulcers associated with Behçet's disease (BD) through week 12.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04528082
Study type Interventional
Source Amgen
Contact Amgen Call Center
Phone 866-572-6436
Email medinfo@amgen.com
Status Recruiting
Phase Phase 3
Start date September 9, 2021
Completion date July 1, 2028
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Terminated NCT04609397 - A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease Phase 2
Not yet recruiting NCT05128357 - IMPACT_BD (IMProving AdherenCe to Treatment in Behçet's Disease)
Not yet recruiting NCT04126850 - Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease
Recruiting NCT05879419 - Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Phase 4
Completed NCT03209219 - Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis Phase 3
Completed NCT04386824 - Erectile Dysfunction in Patients With Non Ocular Behçet's Disease
Completed NCT02648581 - Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease Phase 2
Recruiting NCT04530461 - Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases
Not yet recruiting NCT06386744 - Dusquetide for the Treatment of Behcet's Disease Phase 2
Recruiting NCT04334031 - Deployment o the Multidisciplinary Prospective Cohort Imminent N/A
Not yet recruiting NCT04105439 - Plasma Soluble Urokinase Plasminogen Activator Receptor and Behçet's Disease .
Not yet recruiting NCT05715294 - The Effect of Music on Sleep Quality in Behçet's Patients N/A
Active, not recruiting NCT06266247 - How Sirtuin Levels Change During Behçet Disease N/A
Recruiting NCT04959435 - Understanding the Role of Oral Microbiota in Behçet's Disease (BEHCETBIOT)
Recruiting NCT03837236 - Inactivity Behavior and Exercise Bariers in Patients With Behçet Disease N/A
Recruiting NCT03803462 - Behçet's Disease Overall Damage Index